Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.54 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.39 |
| ▸ | FFAR1 | O14842 | 1/20 | 0.37 |
| ▸ | LMNA | P02545 | 1/20 | 0.37 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.37 |
| ▸ | NR4A2 | P43354 | 1/20 | 0.37 |
| ▸ | CREBBP | Q92793 | 1/20 | 0.37 |
| ▸ | BAZ2B | Q9UIF8 | 1/20 | 0.36 |
| ▸ | BAZ2A | Q9UIF9 | 1/20 | 0.36 |
| ▸ | GAA | P10253 | 1/20 | 0.35 |
| ▸ | HPGD | P15428 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL69740 | 0.80 | NR4A2 (0.48) | ALDH1A1LMNANR4A2CREBBPGAA | |
| SCHEMBL261551 | 0.72 | NOTUM (0.52) | ALDH1A1LMNANR4A2CREBBPGAA | |
| SCHEMBL1156156 | 0.72 | NR4A2 (0.40) | ALDH1A1LMNASMN1; SMN2NR4A2CREBBP | |
| SCHEMBL2654324 | 0.70 | ALDH1A1 (0.57) | ALDH1A1TDP1SMN1; SMN2GAAHPGD | |
| SCHEMBL6360802 | 0.70 | NPSR1 (0.49) | ALDH1A1TDP1LMNASMN1; SMN2GAA | |
| SCHEMBL3563589 | 0.70 | MAPT (0.55) | ALDH1A1LMNANR4A2CREBBPGAA | |
| SCHEMBL1156440 | 0.69 | NR4A2 (0.41) | ALDH1A1LMNANR4A2CREBBPBAZ2B | |
| SCHEMBL28130079 | 0.69 | ALDH1A1 (0.41) | ALDH1A1FFAR1LMNAHPGD | |
| SCHEMBL1155989 | 0.69 | NOTUM (0.58) | ALDH1A1TDP1LMNANR4A2CREBBP | |
| SCHEMBL9549453 | 0.67 | KDM4E (0.50) | ALDH1A1LMNANR4A2CREBBPGAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6770646-B2 | PYRROLO-, THIENO-, FURANO-AND PYRAZOLO-(3,4-D)-PYRIDAZINONES; USED FOR TREATING REVERSIBLE OBSTRUCTIVE AIRWAYS DISEASE AND EFFECTING IMMUNOSUPPRESSION | ASTRAZENECA AB (SE) | 2004-08-03 | — | — | US | disclosed |
| EP-1036076-B1 | NOVEL COMPOUNDS | ASTRAZENECA UK LTD (GB) | 2002-09-04 | — | — | EP | disclosed |
| US-20020099055-A1 | Novel compounds | ASTRAZENECA AB. | 2002-07-25 | — | — | US | disclosed |
| US-6342601-B1 | TREATING ALLOGRAFT REJECTION, RHEUMATOID ARTHRITIS | ASTRAZENECA AB (SE) | 2002-01-29 | — | — | US | disclosed |
| EP-1036076-A1 | NOVEL COMPOUNDS | AstraZeneca UK Limited (GB) | 2000-09-20 | — | — | EP | disclosed |
| WO-1999029695-A1 | NOVEL COMPOUNDS | ASTRAZENECA UK LIMITED (GB) | 1999-06-17 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020099055-A1 | Novel compounds | THPO, CYP4B1, CYP3A4 | ALDH1A1 2122/4885TDP1 3244/4885FFAR1 3890/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.